BioXcel Therapeutics Inc at UBS Global Healthcare Virtual Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Colin Nigel Bristow - UBS Investment Bank, Research Division - Analyst : That's great. Thanks, Will. So we have a question in the system, actually. When does BioXcel plan on initiating a new delirium Phase II trial?

Question: Colin Nigel Bristow - UBS Investment Bank, Research Division - Analyst : That's great. It's helpful. And then one by my e-mail is what is the stage of launch preparation you're at for 501, obviously, in the agitation in schizophrenia and bipolar settings?

Question: Colin Nigel Bristow - UBS Investment Bank, Research Division - Analyst : Yes.

Question: Colin Nigel Bristow - UBS Investment Bank, Research Division - Analyst : Okay. Great. And what are you -- what can you tell us about how you're thinking about pricing for 501 and what interactions have you had to date with payers?

Question: Colin Nigel Bristow - UBS Investment Bank, Research Division - Analyst : Okay. And how should we think about launch trajectory? Is there -- can you give us an ounce that we should be thinking about as examples of launches or anything you can say there, that would be helpful to us.

Question: Colin Nigel Bristow - UBS Investment Bank, Research Division - Analyst : Okay, great. And then on 501 in dementia, for the Phase III program, I think you're expecting to initiate in the second half. Anything you can tell us about the anticipated trial design endpoints?

Question: Colin Nigel Bristow - UBS Investment Bank, Research Division - Analyst : And when do we expect to see the data from the 40-microgram cohort? And can you just talk us to the importance of that?

Question: Colin Nigel Bristow - UBS Investment Bank, Research Division - Analyst : Okay. That's helpful. And then on -- in terms of the opioid withdrawal setting, what are the critical time lines of the next steps for that program?

Question: Colin Nigel Bristow - UBS Investment Bank, Research Division - Analyst : Okay. And no early thoughts on how you're going to manage or fentanyl issue?

Question: Colin Nigel Bristow - UBS Investment Bank, Research Division - Analyst : Okay. Great. Well, maybe give you a breather and we'll switch to Vince on 701. I think we're expecting to get another cut of the interim data from the Phase Ib/II trial in prostate cancer on midyear, but this is being pushed to the second half. What was the reason -- Vince, do we have you?

Question: Colin Nigel Bristow - UBS Investment Bank, Research Division - Analyst : Definitely. Yes.

Question: Colin Nigel Bristow - UBS Investment Bank, Research Division - Analyst : Okay. That's great. And then the basket study in solid tumors, can you talk about what we'll see at ASCO -- what you are hoping to see and what the steps are?

Question: Colin Nigel Bristow - UBS Investment Bank, Research Division - Analyst : Okay. Great. And then maybe just we're approaching the end of the time, but yes, we'll -- Vince, maybe you could just comment on beyond 501, 701, what should we be looking out for there?